In particular, osimertinib, as a third-generation EGFR-TKI, is administered as a first-line treatment2, but it can also be effective for patients with previously treated NSCLC harboring T790M-positive EGFR mutation, based on the AURA3 trial3. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.